NaomiHaasMD

Genitourinary Oncology

Physician

Dr. Haas is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Temple University Hospital-Fox Chase Cancer CenterFellowship, Hematology and Medical Oncology, 1988 - 1991
Abington Memorial HospitalResidency, Internal Medicine, 1985 - 1988
Northeast Ohio Medical UniversityClass of 1985

PubMed

Nivolumab Plus Ipilimumab with Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma.
Michael C Soulen, Naomi B Haas
Journal of Vascular and Interventional Radiology. 2023-06-01
47 citations
BLIMP1 and NR4A3 transcription factors reciprocally regulate antitumor CAR T cell stemness and exhaustion.
In-Young Jung, Vivek Narayan, Sierra McDonald, Andrew J Rech, Robert Bartoszek
Science Translational Medicine. 2022-11-09
39 citations
Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A).
Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, David F McDermott, Mehmet A Bilen
Journal of Clinical Oncology. 2022-09-01

Perelman School of Medicine Awards & Accolades: December 2022January 24th, 2023
Let’s Talk About Sex: Tailoring Prostate-Cancer Care for LGBT+ PeopleSeptember 16th, 2022
Adjuvant Immunotherapy for Kidney Cancer: Is the Future Still Bright?September 11th, 2022
Join now to see all